KEY TAKEAWAYS
- The study aimed to investigate the efficacy and potential benefits of UV-A1 treatment in patients with early-stage MF, focusing on its clinical, histopathological, and immunohistochemical effects.
- Researchers noticed significant improvements in clinical symptoms, histopathological features, and immunohistochemical markers following UVA1 treatment for early-stage MF.
Mycosis fungoides (MF), the most common variant of cutaneous T-cell lymphomas, primarily affects the skin. Early-stage MF presents with non-specific skin lesions and inconclusive biopsies. Although PUVA and narrowband UVB (nbUVB) are commonly recommended treatments, the efficacy of ultraviolet (UVA1) therapy has garnered recent attention.
Nuray Keskin and the team aimed to evaluate the clinical, histopathological, and immunohistochemical effects of UVA1 treatment in patients with early-stage MF.
They performed an inclusive analysis utilizing the modified severity-weighted assessment scale (mSWAT) to conduct total skin body scoring before and after treatment. Skin punch biopsies were obtained from patients both pre- and post-treatment. UVA1 therapy sessions were administered five times weekly.
About 26 patients with early-stage MF were included in the study, undergoing varying numbers of UVA1 sessions (ranging from 15 to 34). Of these patients, 8 (30.8%) achieved a complete response following treatment. The median mSWAT score significantly decreased from 7.1 to 2.0 post-treatment (P < .001).
Histopathological complete response was observed in 2 (9.5%) of 21 patients, with a statistically significant reduction in dermal interstitial infiltrate after treatment (P = .039). Additionally, epidermal CD4/CD8 levels significantly decreased from a median of 2.5 to 1.2 in the complete clinical response group post-treatment (P = .043).
The study concluded that UVA1 treatment demonstrates efficacy in early-stage MF, exerting effects on clinical presentation, histopathological characteristics, and immunohistochemical markers.
Source: https://pubmed.ncbi.nlm.nih.gov/38288765/
Keskin N, Temel B, Adışen E, et al. (2024). “Clinical, histopathological and immunohistochemical evaluation of ultraviolet A1 treatment in early-stage mycosis fungoides.” Photodermatol Photoimmunol Photomed. 2024 Jan;40(1):e12951. doi: 10.1111/phpp.12951. PMID: 38288765.
